Evaluation of auto-antibody serum biomarkers for breast cancer screening and in silico analysis of sero-reactive proteins

Parvez Syed, Klemens Vierlinger, Albert Kriegner, Khulan Sergelen, Johana Luna-Coronell, Christine Rappaport-Fürhauser, Christa Nöhammer, Christian F Singer, Andreas Weinhäusel


Aberrantly expressed proteins in tumours evoke an immunological response. These immunogenic proteins can serve as potential biomarkers for the early diagnosis of cancers. In this study, we performed a candidate marker screen on macroarrays containing 38,016 human proteins, derived from a human fetal-brain expression library, with the pools of sera from breast cancer patients (1 pool of benign samples, 3 pools of ductal carcinoma and 2 pools of lobular carcinoma) and 1 pool of sera from healthy women. A panel of 642 sero-reactive clones were deduced from these macroarray experiments which include 284 in-frame clones. Over-representation analyses of the sero-reactive in-frame clones enabled the identification of the sets of genes over-expressed in various pathways of the functional categories (KEGG, Transpath, Pfam and GO). Protein microarrays, generated using the His-tag proteins derived from the macroarray experiments, were used to evaluate the sera from breast cancer patients (24 malignant, 16 benign) and 20 control individuals. Using the PAM algorithm we elucidated a panel of 50 clones which enabled the correct classification prediction of 93% of the breast-nodule positive group (benign & malignant) sera from healthy individuals’ sera with 100% sensitivity and 85% specificity. This was followed by over-representation analysis of the significant clones derived from the class prediction.


Auto-antibody biomarker; breast cancer; protein microarray; tumour-associated antigens


Abendstein B, Marth C, Muller-Holzner E, Widschwendter M, Daxenbichler G & Zeimet AG 2000 Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer 88 1432-1437.

Anderson KS & LaBaer J 2005 The sentinel within: exploiting the immune system for cancer biomarkers. J.Proteome.Res. 4 1123-1133.

Atalay C, Atalay G, Yilmaz KB & Altinok M 2005 The role of anti-CENP-B and anti-SS-B antibodies in breast cancer. Neoplasma 52 32-35.

Atalay C, Dogan L & Atalay G 2010 Anti-CENP-B antibodies are associated with prolonged survival in breast cancer. Future Oncol 6 471-477.

Babel I, Barderas R, az-Uriarte R, Martinez-Torrecuadrada JL, Sanchez-Carbayo M & Casal JI 2009 Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol Cell Proteomics 8 2382-2395.

Backes C, Keller A, Kuentzer J, Kneissl B, Comtesse N, Elnakady YA, Muller R, Meese E & Lenhof HP 2007 GeneTrail--advanced gene set enrichment analysis. Nucleic Acids Res 35 W186-W192.

Bataller L, Wade DF, Graus F, Rosenfeld MR & Dalmau J 2003 The MAZ protein is an autoantigen of Hodgkin's disease and paraneoplastic cerebellar dysfunction. Ann Neurol 53 123-127.

Bateman A, Coin L, Durbin R, Finn RD, Hollich V, Griffiths-Jones S, Khanna A, Marshall M, Moxon S, Sonnhammer EL, Studholme DJ, Yeats C & Eddy SR 2004 The Pfam protein families database. Nucleic Acids Res 32 D138-D141.

Bradley SV, Oravecz-Wilson KI, Bougeard G, Mizukami I, Li L, Munaco AJ, Sreekumar A, Corradetti MN, Chinnaiyan AM, Sanda MG & Ross TS 2005 Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res 65 4126-4133.

Briasoulis E, Kamposioras K, Tzovaras V, Pafitanis G, Kostoula A, Mavridis A & Pavlidis N 2008 CENP-B specific anti-centromere autoantibodies heralding small-cell lung cancer. A case study and review of the literature. Lung Cancer 60 302-306.

Büssow K, Nordhoff E, Lubbert C, Lehrach H & Walter G 2000 A human cDNA library for high-throughput protein expression screening. Genomics 65 1-8.

Carter D, Dillon DC, Reynolds LD, Retter MW, Fanger G, Molesh DA, Sleath PR, McNeill PD, Vedvick TS, Reed SG, Persing DH & Houghton RL 2003 Serum antibodies to lipophilin B detected in late stage breast cancer patients. Clin Cancer Res 9 749-754.

Casiano CA, Mediavilla-Varela M & Tan EM 2006 Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics 5 1745-1759.

Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, Barnes A & Robertson J 2007 Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 18 868-873.

Chopra P: Data Mining Techniques to Enable Large-scale Exploratory Analysis of Heterogeneous Scientific Data. PhD Thesis. North Carolina State University, Department of Computer Science; 2009.

Conroy SE, Gibson SL, Brunstrom G, Isenberg D, Luqmani Y & Latchman DS 1995 Autoantibodies to 90 kD heat-shock protein in sera of breast cancer patients. Lancet 345 126.

Dalifard I, Daver A & Larra F 1999 Cytosolic p53 protein and serum p53 autoantibody evaluation in breast cancer. Comparison with prognostic factors. Anticancer Res 19 5015-5022.

Desmetz C, Bascoul-Mollevi C, Rochaix P, Lamy PJ, Kramar A, Rouanet P, Maudelonde T, Mange A & Solassol J 2009 Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res 15 4733-4741.

Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB & . 1994 Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54 16-20.

Ferlay J, Parkin DM & Steliarova-Foucher E 2010 Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46 765-781.

Fernandez-Madrid F, Tang N, Alansari H, Granda JL, Tait L, Amirikia KC, Moroianu M, Wang X & Karvonen RL 2004 Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer. Cancer Res 64 5089-5096.

Kanehisa M, Goto S, Kawashima S, Okuno Y & Hattori M 2004 The KEGG resource for deciphering the genome. Nucleic Acids Res 32 D277-D280.

Keller A, Backes C & Lenhof HP 2007 Computation of significance scores of unweighted Gene Set Enrichment Analyses. BMC Bioinformatics 8 290.

Koziol JA, Zhang JY, Casiano CA, Peng XX, Shi FD, Feng AC, Chan EK & Tan EM 2003 Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 9 5120-5126.

Krull M, Pistor S, Voss N, Kel A, Reuter I, Kronenberg D, Michael H, Schwarzer K, Potapov A, Choi C, Kel-Margoulis O & Wingender E 2006 TRANSPATH: an information resource for storing and visualizing signaling pathways and their pathological aberrations. Nucleic Acids Res 34 D546-D551.

Kulic A, Sirotkovic-Skerlev M, Jelisavac-Cosic S, Herceg D, Kovac Z & Vrbanec D 2010 Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients. Med Oncol 27 887-893.

Lee D, Redfern O & Orengo C 2007 Predicting protein function from sequence and structure. Nat Rev Mol Cell Biol 8 995-1005.

Leidinger P, Keller A, Heisel S, Ludwig N, Rheinheimer S, Klein V, Andres C, Hamacher J, Huwer H, Stephan B, Stehle I, Lenhof HP & Meese E 2009 Novel autoantigens immunogenic in COPD patients. Respir Res 10 20.

Li L, Chen SH, Yu CH, Li YM & Wang SQ 2008 Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray. J Proteome Res 7 611-620.

Liang QJ, Lu XF, Cheng XL, Luo S, He DC & Wang YC 2004 [The active expression of CenpB, a constitutive protein in the centromeres of chromosomes, in breast cancer tissues]. Yi.Chuan Xue Bao. 31 236-240.

Liu H, Zhang J, Wang S, Pang Z, Wang Z, Zhou W & Wu M 2011a Screening of autoantibodies as potential biomarkers for hepatocellular carcinoma by using T7 phase display system. Cancer Epidemiol doi:10.1016/j.canep.2011.04.001.

Liu X, Lv B & Guo W 2011b The size distribution of protein families within different types of folds. Biochem Biophys Res Commun 406 218-222.

Looi K, Megliorino R, Shi FD, Peng XX, Chen Y & Zhang JY 2006 Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. OncolRep 16 1105-1110.

Looi KS, Nakayasu ES, Diaz RA, Tan EM, Almeida IC & Zhang JY 2008 Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res 7 4004-4012.

Lu D, Kuhn E, Bristow RE, Giuntoli RL, Kjaer SK, Shih I & Roden RB 2011 Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol 122 560-566.

Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, Hirsch A & Soussi T 1995 Serum p53 antibodies as early markers of lung cancer. Nat Med 1 701-702.

Ludwig N, Keller A, Heisel S, Leidinger P, Klein V, Rheinheimer S, Andres CU, Stephan B, Steudel WI, Graf NM, Burgeth B, Weickert J, Lenhof HP & Meese E 2009 Improving seroreactivity-based detection of glioma. Neoplasia 11 1383-1389.

Messmer BT, Nour-Omid TS, Ghia E, Sanchez AB & Kipps TJ 2011 Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia. Leuk Res 35 965-967.

Nakano M, Ohuchi Y, Hasegawa H, Kuroda T, Ito S & Gejyo F 2000 Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus. J Rheumatol 27 1403-1407.

Nesterova MV, Johnson N, Cheadle C, Bates SE, Mani S, Stratakis CA, Khan IU, Gupta RK & Cho-Chung YS 2006 Autoantibody cancer biomarker: extracellular protein kinase A. Cancer Res 66 8971-8974.

Piura E & Piura B 2011 Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma. J Oncol 2011 982425.

Preininger C, Bodrossy L, Sauer U, Pichler R & Weilharter A 2004 ARChip epoxy and ARChip UV for covalent on-chip immobilization of pmoA gene-specific oligonucleotides. Anal Biochem 330 29-36.

R Development Core Team 2005 R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing.

Sanchez-Carbayo M 2006 Antibody arrays: technical considerations and clinical applications in cancer. Clin Chem 52 1651-1659.

Schacherer F, Choi C, Gotze U, Krull M, Pistor S & Wingender E 2001 The TRANSPATH signal transduction database: a knowledge base on signal transduction networks. Bioinformatics 17 1053-1057.

Schmitt J, Heisel S, Keller A, Leidinger P, Ludwig N, Habel N, Furtwangler R, Nourkami-Tutdibi N, Wegert J, Grundy P, Gessler M, Graf N, Lenhof HP & Meese E 2011 Multicenter study identified molecular blood-born protein signatures for Wilms Tumor. Int J Cancer doi: 10.1002/ijc.26419.

Simon R & Lam A 2009 BRB-ArrayTools User Guide, version 3.2. Biometric Research Branch, National Cancer Institute. http://linus.nci.nih.gov/brb. Biometric Research Branch, National Cancer Institute. http://linus.nci.nih.gov/brb.

Soussi T 2000 p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60 1777-1788.

Stempfer R, Syed P, Vierlinger K, Pichler R, Meese E, Leidinger P, Ludwig N, Kriegner A, Nohammer C & Weinhausel A 2010 Tumour auto-antibody screening: performance of protein microarrays using SEREX derived antigens. BMC Cancer 10 627.

Suzuki A, Iizuka A, Komiyama M, Takikawa M, Kume A, Tai S, Ohshita C, Kurusu A, Nakamura Y, Yamamoto A, Yamazaki N, Yoshikawa S, Kiyohara Y & Akiyama Y 2010 Identification of melanoma antigens using a Serological Proteome Approach (SERPA). Cancer Genomics Proteomics 7 17-23.

The Gene Ontology Consortium 2000 Gene ontology: tool for the unification of biology. Nat Genet 25 25-29

Tibshirani R, Hastie T, Narasimhan B & Chu G 2002 Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U.S.A 99 6567-6572.

Tomaino B, Cappello P, Capello M, Fredolini C, Ponzetto A, Novarino A, Ciuffreda L, Bertetto O, De AC, Gaia E, Salacone P, Milella M, Nistico P, Alessio M, Chiarle R, Giuffrida MG, Giovarelli M & Novelli F 2007 Autoantibody signature in human ductal pancreatic adenocarcinoma. J Proteome Res 6 4025-4031.

Trivers GE, De B, V, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD & Harris CC 1996 Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 2 1767-1775.

Zaytseva YY, Wang X, Southard RC, Wallis NK & Kilgore MW 2008 Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells. Mol Cancer 7 90.

Zhang J, Wang K, Zhang J, Liu SS, Dai L & Zhang JY 2011 Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res 10 2863-2872.

Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK & Tan EM 2003 Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 12 136-143.

Zhong L, Ge K, Zu JC, Zhao LH, Shen WK, Wang JF, Zhang XG, Gao X, Hu W, Yen Y & Kernstine KH 2008 Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Res 10 R40.

Full Text: PDF


  • There are currently no refbacks.

Copyright © 2018 Lorem Ipsum Press